- Home
- DHY vs ZVRA Comparison
DHY vs ZVRA Comparison
Compare DHY & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHY
- ZVRA
- Stock Information
- Founded
- DHY 1998
- ZVRA 2006
- Country
- DHY United States
- ZVRA United States
- Employees
- DHY N/A
- ZVRA N/A
- Industry
- DHY Finance/Investors Services
- ZVRA Biotechnology: Pharmaceutical Preparations
- Sector
- DHY Finance
- ZVRA Health Care
- Exchange
- DHY Nasdaq
- ZVRA Nasdaq
- Market Cap
- DHY 217.4M
- ZVRA 385.2M
- IPO Year
- DHY N/A
- ZVRA 2015
- Fundamental
- Price
- DHY $2.15
- ZVRA $7.32
- Analyst Decision
- DHY
- ZVRA Strong Buy
- Analyst Count
- DHY 0
- ZVRA 5
- Target Price
- DHY N/A
- ZVRA $21.00
- AVG Volume (30 Days)
- DHY 569.1K
- ZVRA 791.9K
- Earning Date
- DHY 01-01-0001
- ZVRA 08-13-2024
- Dividend Yield
- DHY 9.10%
- ZVRA N/A
- EPS Growth
- DHY N/A
- ZVRA N/A
- EPS
- DHY N/A
- ZVRA N/A
- Revenue
- DHY N/A
- ZVRA $23,689,000.00
- Revenue This Year
- DHY N/A
- ZVRA N/A
- Revenue Next Year
- DHY N/A
- ZVRA $220.63
- P/E Ratio
- DHY N/A
- ZVRA N/A
- Revenue Growth
- DHY N/A
- ZVRA 43.21
- 52 Week Low
- DHY $1.77
- ZVRA $3.89
- 52 Week High
- DHY $2.08
- ZVRA $8.44
- Technical
- Relative Strength Index (RSI)
- DHY 64.06
- ZVRA 55.49
- Support Level
- DHY $2.12
- ZVRA $7.05
- Resistance Level
- DHY $2.10
- ZVRA $7.84
- Average True Range (ATR)
- DHY 0.02
- ZVRA 0.44
- MACD
- DHY 0.00
- ZVRA -0.06
- Stochastic Oscillator
- DHY 90.00
- ZVRA 57.02
About DHY Credit Suisse High Yield Bond Fund
Credit Suisse High Yield Bond Fund is a non-diversified, closed-end management investment company with the objective to seek high current income and capital appreciation as a secondary objective.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.